FP11 Stock Chart & Stats
€5.23
--
Market closed
€5.23
--
Day’s Range― - ―
52-Week Range€4.20 - €70.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€1.51M
Enterprise Value-€4.66M
Total Cash (Recent Filing)€8.29M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet reduces solvency and interest-cost pressure while preserving flexibility for clinical development. Although the company is consuming equity, the absence of borrowings limits refinancing exposure and avoids debt claims competing with research funding.
PIPE Funding For Clinical DevelopmentThe PIPE supplies near-term capital for advancing the lead antiviral program, which may extend the operating runway and support key clinical milestones. Funding tied to development progress also indicates that an institutional investor is willing to finance the platform at this stage.
Losses Largely Reflect Cash SpendingFree cash flow broadly tracking net losses suggests the reported losses are primarily associated with actual operating cash use rather than large non-cash accounting charges. This improves the quality and transparency of the loss profile, even though the underlying cash burn remains substantial.
Bears Say
Pre-revenue Business ModelThe company has not yet established commercial revenue, leaving its business model dependent on successful clinical development before it can generate operating income. This creates a long path to self-funded growth and makes future financial performance highly dependent on trial progress.
Persistent And Accelerating Cash BurnNegative operating and free cash flow indicate that ongoing activities consume substantial cash, with TTM operating burn worsening from 2025. Continued spending without revenue increases the need for additional financing and can constrain the pace and scope of future development.
Shrinking Equity And Dilution RiskThe steep reduction in equity shows that sustained losses have materially consumed the capital base. With no revenue and ongoing cash burn, further funding may be required, creating dilution risk and reducing existing shareholders’ participation in any eventual clinical or commercial upside.
Decoy Therapeutics News
FP11 FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was €4.20 and its highest was €70.80 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is €1.51M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Currently, no data Available
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DE:FP11
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Technical Analysis
Oragenics
―
Moleculin Biotech
―
Propanc Biopharma
―
Genprex
―
Calidi Biotherapeutics
―